348 results
Page 4 of 18
8-K
qos2 yia5
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-4.1
yh1njy9acguq mie
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-10.1
1v3d4a0o
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-99.1
ra8aizumlzgk8t5hz
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-5.1
nt4ir2n3m8wbsjjp
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
424B5
wxnoyl
27 Apr 20
Prospectus supplement for primary offering
7:30am
8-K
EX-10.1
jp6 hmfknxqqykj
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-99.1
u5ovvb0pt vc7
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
vrp 5agv2ftifm1t9inf
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-5.1
5raqy5b3q3n66
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-4.1
0x8km l3d6o676l
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-99.2
qdv6 xnikg
5 Mar 20
Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
4:07pm
8-K
EX-99.2
c0vtroaliat
18 Nov 19
Caladrius Biosciences Reports Positive Results for CLBS16 from the ESCaPE-CMD Trial at American Heart Association Scientific Sessions 2019
6:21am
424B5
47mnr
20 Mar 19
Prospectus supplement for primary offering
5:19pm
424B5
go3hy9n0ojd4
14 Mar 19
Prospectus supplement for primary offering
4:23pm
8-K
EX-10.1
8l6p du504v
14 Mar 19
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
4:18pm